Transcode Therapeutics, Inc. (RNAZ) Form 8-K — Oct 1, 2026
TransCode Therapeutics disclosed that its stock traded below the $1.72 floor price on 10 of 14 trading days between September 11 and September 30, 2026, risking an Amortization Event under its Yorkville convertible notes. On October 1, 2026, the company paid Yorkville $840,975 — including $759,000 principal, a $75,900 prepayment premium, and $6,075 interest — in exchange for a waiver of amortization events through October 31, 2026. After the prepayment, approximately $4.1 million remains outstanding under the convertible notes, which are part of an arrangement allowing TransCode to sell up to $14 million of stock to Yorkville with up to $6.0 million of note advances.
Key figures
- Debt Amount
- $14 million SEPA commitment; $4.1 million convertible notes outstanding after prepayment
- Floor price
- 1.72
- Waiver through
- October 31, 2026
- Prepayment amount
- 840975
- Prepayment premium
- 75900
- Prepayment principal
- 759000
- Accrued interest paid
- 6075
- Vwap below floor days
- 10 of 14 trading days, Sept 11-30, 2026
- Yorkville advance capacity
- 6000000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.